Quintiles is the industry leader that best differentiates itself on service quality in Phase II/III clinical research, according to 157 pharmaceutical and biotechnology professionals who responded to Industry Standard Research’s (ISR) 2013 CRO Quality Benchmarking Report"......

Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that results from a prospective, multicenter, randomized, controlled clinical trial show that endoscopic ablation therapy using the Barrx™ RF Ablation System is effective at eliminating Barrett’s esophagus, a pre-cancerous condition of the esophagus, and preventing disease progression.

...

• Tiotropium delivered by the Respimat® SoftMistTM Inhaler increases time to first severe exacerbation and first episode of asthma worsening across a broad spectrum of patients who remain symptomatic despite at least ICS/LABA therapy
• The improvements in lung function with tiotropium were specific to asthma patients; as a co-morbid condition, chronic obstructive pulmonary disease (COPD) was excluded in this trial

For Media outside the U.S., Canada and UK

In"...

After years of low productivity, R&D in leading pharmaceutical and biotech companies is starting to deliver on its promises; the number of New Molecular Entities (NMEs) approved by the US FDA has leveled out and biotech companies’ share prices are rising, indicating profitable business models. Now is the time for launch. Arthur D. Little’s (ADL) latest viewpoint, ‘Launch excellence for new medicines,’ assesses the key success factors for the successful launch of new medicines.

...

Kinetic Concepts, Inc. announced today that ABThera™ Open Abdomen Negative Pressure Therapy System (ABThera™ OA NPT) was associated with significantly improved patient outcomes compared to traditional Barker’s vacuum-packing technique (BVPT) in trauma and surgical patients studied. Results"...

Quintiles today announced the completion of its initial public offering of 27,236,841 shares of its common stock at a price to the public of $40.00 per share. Quintiles offered and sold 13,125,000 shares of common stock in the offering and selling shareholders offered and sold 14,111,841 shares of common stock in the offering, including 3,552,631 shares that were offered and sold by the selling shareholders pursuant to the full exercise of the underwriters’ option to purchase additional shares.

...

Growing body of clinical data supports superiority of the irreversible ErbB Family Blocker afatinib* over standard chemotherapy (with combination of cisplatin and gemcitabine or pemetrexed) for first-line treatment of patients with EGFR-mutation positive advanced NSCLC

First set of Phase III results unveiled from LUME-Lung clinical trial programme investigating triple angiokinase"...

Merck Serono, a division of Merck, Darmstadt, Germany, and Quintiles, the world’s largest provider of biopharmaceutical development and commercial outsourcing services, today announced a new, five-year clinical development agreement. This strategic collaboration is the first-of-its-kind between a biopharmaceutical company and a biopharmaceutical services provider, creating a comprehensive process that integrates the expertise and experience from both organizations into a single, well-aligned clinical development engine.

In"...

New evidence presented on Wednesday 15th May 2013 at the European Wound Management Association (EWMA)’s conference in Copenhagen, revealed that elevated protease activity (EPA) was detected in almost half the wounds (43%) that resulted in skin graft failure1.

In the thirty patient"......

Lincor Solutions Launches World’s First Mobile Solution for Patient Engagement and Clinical Services

MEDIVista MOBILE delivers services to Apple iPad and Android devices

eHealth Week

Lincor announces the latest addition to the MEDIVista product suite – MEDIVista MOBILE, during eHealth Week in Dublin.

MEDIVista MOBILE delivers patient services to iPads and Android wireless tablets and is a modular extension to the proven MEDIVista service delivery platform"......